News

SIU Med School Is Exclusive Site for Bladder Cancer Clinical Trial

Published Date:

Combined Drug Therapies May Prevent Need for Surgery

A new clinical trial for bladder cancer has opened exclusively at Southern Illinois University School of Medicine in Springfield. The trial will combine the current use of drug therapy placed inside the bladder with a new, intravenous drug that increases the response of the immune system. The study will determine if the combination of the two drugs is safe and potentially be more effective at eliminating the cancer cells. The new drug, pembrolizumab, may fight the disease and prevent the need for surgery.

Dr. Shaheen Alanee, assistant professor at Southern Illinois University School of Medicine, head of urologic oncology and a member of Simmons Cancer Institute (SCI) at SIU, said the trial is for aggressive, high-risk superficial bladder cancer that has not invaded the muscle of the wall of the bladder. Patients eligible for the clinical trial continue to have the disease despite previous treatment. “These patients have limited options for therapy other than surgery,”Alanee said. “No good medical therapy exists for patients who fail initial treatment, and that is what made us think of this regimen.”

Fifteen to twenty patients will be enrolled in the trial. Study participants will be treated with pembrolizumab before other treatments begin. Pembrolizumab will continue for six weeks during the course of traditional treatment and stopped several weeks after the BCG regimen is finished.

Patients will receive treatment over the course of four months. Study follow up will monitor progression of the disease or for two years following completion of the treatment, whichever occurs first.

About 50,000 cases of bladder cancer are diagnosed in the United States every year. Presently, if a patient has a recurrence of bladder cancer, the options for therapy are very limited besides surgery. The surgery entails removing the bladder and connecting the kidneys to the outside using a segment of the small bowel. “If the trial is successful, patients could be spared a major surgery with a very high risk of complications.”

The mission of Simmons Cancer Institute at SIU is to serve the people of central and southern Illinois by addressing their present and future cancer needs through education, research, patient care and community service. For more information about this and other cancer related trials at Simmons Cancer Institute call 217-545-1946 or visit www.siumed.edu/cancer.

More from SIU News

Sophia Ran, PhD funding story

Science, scrutiny and staying power: Dr. Sophia Ran’s two decades of cancer research

The rules of scientific research have changed dramatically over the past two decades. Grants are more competitive. Expectations for rigor, repeatability and transparency are higher. And researchers
Iris Wesley

A heart for the mission, a mind for the work: Iris Wesley’s vision broadens care in Illinois

Over more than 40 years at SIU Medicine, Iris Wesley played a key role in expanding access to care across Illinois. Her collaborative leadership helped guide the growth of SIU’s Federally Qualified Health Center network, now one of the largest university-affiliated systems in the country.
Jessica Barney and Vistrit Choudhary

Forty Under 40 honors SIU Medicine professionals

The Springfield Business Journal celebrates 40 professionals under 40 in our local community each year. As part of the 2025 class, SIU Medicine’s Jessica Barney and Vistrit Choudhary have been honored